PURPOSE: Acute exacerbations (AE) in patients with COPD are associated with a decline in lung function, increased risk of hospitalization, and mortality. In this cross-sectional study we tested whether the level of objectively measured daily physical activity and exercise capacity are associated with the number of COPD exacerbations. METHODS: In 210 patients with COPD (67 % men; mean (SD) age: 63 (8) years) enrolled in The Obstructive Pulmonary Disease Outcomes Cohort of Switzerland (TOPDOCS) physical activity (PA) (steps per day, physical activity level, (PAL)), exercise capacity (6-min walking distance, (6MWD)), comorbidities, lung function, and medication were assessed. Differences between COPD patients with frequent (≥2 year) and infrequent (0-1 year) exacerbations were assessed. Univariate and multivariate analyses were performed to investigate whether the level of objectively measured daily physical activity and exercise capacity are associated with the number of COPD exacerbations. RESULTS: Patients with frequent AE had a significantly lower FEV1 and 6MWD compared to patients with infrequent AE. In univariate analysis, the number of exacerbations was inversely associated with FEV1, 6MWD, BMI, and smoking status while there was a positive association with RV/TLC and combined inhaled medication. However, there was no significant association with PAL and steps per day. In multivariate analysis, FEV1 and the use of combined inhaled medication were independently associated with the number of AE, after correction for covariates. CONCLUSIONS: The findings of this study imply that FEV1, independent of inhaled medication, is significantly associated with COPD exacerbations. Neither physical activity nor exercise capacity was independently associated with COPD exacerbations.
PURPOSE: Acute exacerbations (AE) in patients with COPD are associated with a decline in lung function, increased risk of hospitalization, and mortality. In this cross-sectional study we tested whether the level of objectively measured daily physical activity and exercise capacity are associated with the number of COPD exacerbations. METHODS: In 210 patients with COPD (67 % men; mean (SD) age: 63 (8) years) enrolled in The Obstructive Pulmonary Disease Outcomes Cohort of Switzerland (TOPDOCS) physical activity (PA) (steps per day, physical activity level, (PAL)), exercise capacity (6-min walking distance, (6MWD)), comorbidities, lung function, and medication were assessed. Differences between COPD patients with frequent (≥2 year) and infrequent (0-1 year) exacerbations were assessed. Univariate and multivariate analyses were performed to investigate whether the level of objectively measured daily physical activity and exercise capacity are associated with the number of COPD exacerbations. RESULTS:Patients with frequent AE had a significantly lower FEV1 and 6MWD compared to patients with infrequent AE. In univariate analysis, the number of exacerbations was inversely associated with FEV1, 6MWD, BMI, and smoking status while there was a positive association with RV/TLC and combined inhaled medication. However, there was no significant association with PAL and steps per day. In multivariate analysis, FEV1 and the use of combined inhaled medication were independently associated with the number of AE, after correction for covariates. CONCLUSIONS: The findings of this study imply that FEV1, independent of inhaled medication, is significantly associated with COPD exacerbations. Neither physical activity nor exercise capacity was independently associated with COPD exacerbations.
Authors: T A Seemungal; G C Donaldson; E A Paul; J C Bestall; D J Jeffries; J A Wedzicha Journal: Am J Respir Crit Care Med Date: 1998-05 Impact factor: 21.405
Authors: J J Soler-Cataluña; M A Martínez-García; P Román Sánchez; E Salcedo; M Navarro; R Ochando Journal: Thorax Date: 2005-07-29 Impact factor: 9.139
Authors: Judith Garcia-Aymerich; Ignasi Serra; Federico P Gómez; Eva Farrero; Eva Balcells; Diego A Rodríguez; Jordi de Batlle; Elena Gimeno; David Donaire-Gonzalez; Mauricio Orozco-Levi; Jaume Sauleda; Joaquim Gea; Robert Rodriguez-Roisin; Josep Roca; Àlvar G Agustí; Josep M Antó Journal: Chest Date: 2009-03-02 Impact factor: 9.410
Authors: Jørgen Vestbo; Lisa D Edwards; Paul D Scanlon; Julie C Yates; Alvar Agusti; Per Bakke; Peter M A Calverley; Bartolome Celli; Harvey O Coxson; Courtney Crim; David A Lomas; William MacNee; Bruce E Miller; Edwin K Silverman; Ruth Tal-Singer; Emiel Wouters; Stephen I Rennard Journal: N Engl J Med Date: 2011-09-26 Impact factor: 91.245
Authors: Alexander D Zider; Xiaoyan Wang; Russell G Buhr; Worawan Sirichana; Igor Z Barjaktarevic; Christopher B Cooper Journal: Chest Date: 2017-05-05 Impact factor: 9.410
Authors: Simona Tabea Huebner; Simona Henny; Stéphanie Giezendanner; Thomas Brack; Martin Brutsche; Prashant Chhajed; Christian Clarenbach; Thomas Dieterle; Adrian Egli; Martin Frey; Ingmar Heijnen; Sarosh Irani; Noriane Andrina Sievi; Robert Thurnheer; Marten Trendelenburg; Malcolm Kohler; Anne Barbara Leuppi-Taegtmeyer; Joerg Daniel Leuppi Journal: Respiration Date: 2021-12-23 Impact factor: 3.966